Journal
CLINICS IN LIVER DISEASE
Volume 17, Issue 4, Pages 533-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.cld.2013.07.012
Keywords
Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Microvesicular and macrovesicular steatosis; Drug-induced steatohepatitis
Categories
Funding
- NIH
Ask authors/readers for more resources
Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease in the United States. The term NALFD was first used by Ludwig in 1980 to describe the presence of hepatic steatosis and steatohepatitis in a series of patients with no identifiable cause. Since then, our insight into the pathogenesis of NAFLD has expanded significantly. We now know that NAFLD is closely related to metabolic syndrome and chronic low-grade inflammation. In the following review, the authors summarize the current evidence about drugs that lead to hepatic steatosis and steatohepatitis and pathogenic mechanisms thereof.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available